Skip to main content

Table 1 Characteristics of persons contacted, excluded, lost, and enrolled

From: Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes

Characteristic

Contacted, no response

Refused participation

Enrolled, lost before baseline

Enrolled successfully

(n = 6766) n%

(n = 3710) n%

(n = 185) n%

(n = 2966) n%

Age (Years)

    

≤ 30

536 ( 7.9)

164 ( 4.4)

7 ( 3.8)

140 ( 4.7)

31 – 40

1434 (21.2)

517 (13.9)

30 (16.3)

455 (15.3)

41 – 50

2207 (32.6)

1000 (27.0)

54 (29.2)

885 (29.8)

51 – 60

1873 (27.7)

1291 (34.8)

65 (34.9)

1068 (36.0)

≥ 61

716 (10.6)

738 (19.9)

29 (15.8)

418 (14.1)

Gender

    

Female

5200 (76.9)

2815 (75.9)

153 (82.8)

2385 (80.4)

Male

1566 (23.1)

895 (24.1)

32 (17.2)

581 (19.6)

Dispensed DMT:

    

GA

3187 (47.1)

1677 (45.2)

99 (53.6)

1475 (49.7)

IFNβ-1a IM

1504 (22.2)

857 (23.1)

30 (16.3)

604 (20.4)

IFNβ-1a SC

1172 (17.3)

678 (18.3)

29 (15.8)

470 (15.8)

IFNβ-1b

903 (13.3)

498 (13.4)

27 (14.4)

417 (14.1)

  1. DMT, Disease-modifying therapy; IFNβ-1a IM, Intramuscular interferon beta-1a; IFNβ-1b, Interferon beta -1b; GA, Glatiramer acetate; IFNβ-1a SC, Subcutaneous interferon beta-1a.